Logo image of PMN

PROMIS NEUROSCIENCES INC (PMN) Stock Price, Quote, News and Overview

NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD

0.561  -0.03 (-5.68%)

PMN Quote, Performance and Key Statistics

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (4/24/2025, 8:00:00 PM)

0.561

-0.03 (-5.68%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.37
52 Week Low0.51
Market Cap18.34M
Shares32.69M
Float23.68M
Yearly DividendN/A
Dividend YieldN/A
PE6.23
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO04-03 2017-04-03


PMN short term performance overview.The bars show the price performance of PMN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

PMN long term performance overview.The bars show the price performance of PMN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PMN is 0.561 USD. In the past month the price decreased by -23.15%. In the past year, price decreased by -71.67%.

PROMIS NEUROSCIENCES INC / PMN Daily stock chart

PMN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.82 319.07B
AMGN AMGEN INC 14.12 150.46B
GILD GILEAD SCIENCES INC 13.71 132.33B
VRTX VERTEX PHARMACEUTICALS INC 1698.17 126.60B
REGN REGENERON PHARMACEUTICALS 13.14 65.57B
ARGX ARGENX SE - ADR 322.85 36.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.56B
BNTX BIONTECH SE-ADR N/A 28.98B
ONC BEIGENE LTD-ADR N/A 27.60B
SMMT SUMMIT THERAPEUTICS INC N/A 27.06B
NTRA NATERA INC N/A 20.88B
BIIB BIOGEN INC 7.26 17.49B

About PMN

Company Profile

PMN logo image ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Company Info

PROMIS NEUROSCIENCES INC

Suite 200, 1920 Yonge Street

TORONTO ONTARIO CA

Employees: 7

Company Website: https://www.promisneurosciences.com/

Investor Relations: http://www.promisneurosciences.com/investors

Phone: 14168476898

PROMIS NEUROSCIENCES INC / PMN FAQ

What is the stock price of PROMIS NEUROSCIENCES INC today?

The current stock price of PMN is 0.561 USD. The price decreased by -5.68% in the last trading session.


What is the ticker symbol for PROMIS NEUROSCIENCES INC stock?

The exchange symbol of PROMIS NEUROSCIENCES INC is PMN and it is listed on the Nasdaq exchange.


On which exchange is PMN stock listed?

PMN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PROMIS NEUROSCIENCES INC stock?

7 analysts have analysed PMN and the average price target is 7.99 USD. This implies a price increase of 1324.24% is expected in the next year compared to the current price of 0.561. Check the PROMIS NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROMIS NEUROSCIENCES INC worth?

PROMIS NEUROSCIENCES INC (PMN) has a market capitalization of 18.34M USD. This makes PMN a Nano Cap stock.


How many employees does PROMIS NEUROSCIENCES INC have?

PROMIS NEUROSCIENCES INC (PMN) currently has 7 employees.


What are the support and resistance levels for PROMIS NEUROSCIENCES INC (PMN) stock?

PROMIS NEUROSCIENCES INC (PMN) has a resistance level at 0.6. Check the full technical report for a detailed analysis of PMN support and resistance levels.


Should I buy PROMIS NEUROSCIENCES INC (PMN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROMIS NEUROSCIENCES INC (PMN) stock pay dividends?

PMN does not pay a dividend.


When does PROMIS NEUROSCIENCES INC (PMN) report earnings?

PROMIS NEUROSCIENCES INC (PMN) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of PROMIS NEUROSCIENCES INC (PMN)?

The PE ratio for PROMIS NEUROSCIENCES INC (PMN) is 6.23. This is based on the reported non-GAAP earnings per share of 0.09 and the current share price of 0.561 USD. Check the full fundamental report for a full analysis of the valuation metrics for PMN.


What is the Short Interest ratio of PROMIS NEUROSCIENCES INC (PMN) stock?

The outstanding short interest for PROMIS NEUROSCIENCES INC (PMN) is 0.85% of its float. Check the ownership tab for more information on the PMN short interest.


PMN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PMN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PMN. PMN has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PMN Financial Highlights

Over the last trailing twelve months PMN reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 98.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA 14.69%
ROE 16.85%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%96.55%
Sales Q2Q%N/A
EPS 1Y (TTM)98.63%
Revenue 1Y (TTM)N/A

PMN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to PMN. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners29.84%
Ins Owners7.3%
Short Float %0.85%
Short Ratio5.12
Analysts
Analysts85.71
Price Target7.99 (1324.24%)
EPS Next Y-778.94%
Revenue Next YearN/A